Brief: Cadrenal Therapeutics Announces Clinical Trial Initiation Plans For Tecarfarin In Patients With End-Stage Kidney Disease (Eskd) Transitioning To Dialysis
05/08/2025 12:48
Aug 5 (Reuters) - Cadrenal Therapeutics Inc CVKD.O: CADRENAL THERAPEUTICS ANNOUNCES CLINICAL TRIAL INITIATION PLANS FOR TECARFARIN IN PATIENTS WITH END-STAGE KIDNEY DISEASE (ESKD) TRANSITIONING TO DIALYSIS CADRENAL THERAPEUTICS INC - ENROLLMENT FOR TECARFARIN TRIAL TO BEGIN LATER THIS YEAR Source text: ID:nBw3nZ0zya Further company coverage: CVKD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cadrenal Therapeutics
See all newsCadrenal Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Cadrenal Therapeutics Q2 net loss narrows as operating expenses fall
Cadrenal Therapeutics Inc expected to post a loss of $1.42 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Salesforce
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Marvell Technology